
- Oncology NEWS International Vol 4 No 7
- Volume 4
- Issue 7
Interleukin-11 to Enter Phase III
CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.
CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinanthuman interleukin-11 (rhIL-11) restored platelets in throm-bocytopenicpatients undergoing cancer chemotherapy to the extent that significantlyfewer rhIL-11 treated patients required platelet transfusions,compared to placebo.
Based on this favorable outcome, the company plans to begin aphase III study by the end of this year.
Articles in this issue
over 30 years ago
House Panel Holds Hearing on Self-Referralover 30 years ago
Health-Related Legislationover 30 years ago
Mitoguazone Appears Promising in HIV-Associated Refractory NHLover 30 years ago
Responses to Anti-HER2 MoAb Seenover 30 years ago
MoAb May Improve Detection of Colon And Rectal Cancerover 30 years ago
Zeneca Files NDA for ArimidexNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.